0	7	Aspirin	aspirin	NN
8	16	inhibits	inhibit	VBZ
17	24	nuclear	nuclear	JJ
25	37	factor-kappa	factor-kappa	NN
38	39	B	B	NNP
40	52	mobilization	mobilization	NN
53	56	and	and	CC
57	65	monocyte	monocyte	NN
66	74	adhesion	adhesion	NN
75	77	in	in	IN
78	88	stimulated	stimulate	VBN
89	94	human	human	JJ
95	106	endothelial	endothelial	JJ
107	112	cells	cell	NNS
112	113	.	.	.

115	125	BACKGROUND	background	NN
125	126	:	:	:
127	130	The	the	DT
131	140	induction	induction	NN
141	143	of	of	IN
144	152	vascular	vascular	JJ
153	157	cell	cell	NN
158	166	adhesion	adhesion	NN
167	177	molecule-1	molecule-1	NN
178	179	(	(	(
179	185	VCAM-1	vcam-1	NN
185	186	)	)	)
187	190	and	and	CC
191	201	E-selectin	E-selectin	NNP
202	204	by	by	IN
205	210	tumor	tumor	NN
211	219	necrosis	necrosis	NN
220	232	factor-alpha	factor-alpha	NN
233	234	(	(	(
234	237	TNF	TNF	NNP
237	238	)	)	)
239	241	is	be	VBZ
242	250	mediated	mediate	VBN
251	253	by	by	IN
254	266	mobilization	mobilization	NN
267	269	of	of	IN
270	273	the	the	DT
274	287	transcription	transcription	NN
288	294	factor	factor	NN
295	302	nuclear	nuclear	JJ
303	315	factor-kappa	factor-kappa	NN
316	317	B	B	NNP
318	319	(	(	(
319	327	NF-kappa	NF-kappa	NNP
328	329	B	B	NNP
329	330	)	)	)
330	331	.	.	.

332	337	Since	since	IN
338	349	salicylates	salicylate	NNS
350	354	have	have	VBP
355	359	been	be	VBN
360	368	reported	report	VBN
369	371	to	to	TO
372	379	inhibit	inhibit	VB
380	388	NF-kappa	NF-kappa	NNP
389	390	B	B	NNP
391	401	activation	activation	NN
402	404	by	by	IN
405	415	preventing	prevent	VBG
416	419	the	the	DT
420	431	degradation	degradation	NN
432	434	of	of	IN
435	438	its	its	PRP$
439	448	inhibitor	inhibitor	NN
449	450	I	i	NN
451	456	kappa	kappa	NN
457	458	B	B	NNP
458	459	,	,	,
460	462	we	we	PRP
463	470	studied	study	VBD
471	472	a	a	DT
473	482	potential	potential	JJ
483	493	inhibition	inhibition	NN
494	496	of	of	IN
497	501	this	this	DT
502	509	pathway	pathway	NN
510	512	by	by	IN
513	529	acetylsalicylate	acetylsalicylate	NN
530	531	(	(	(
531	538	aspirin	aspirin	NN
538	539	)	)	)
540	542	in	in	IN
543	548	human	human	JJ
549	558	umbilical	umbilical	JJ
559	563	vein	vein	NN
564	575	endothelial	endothelial	JJ
576	581	cells	cell	NNS
582	583	(	(	(
583	589	HUVECs	HUVEC	NNP
589	590	)	)	)
590	591	.	.	.

592	599	METHODS	methods	NNS
600	603	AND	and	CC
604	611	RESULTS	results	NNS
611	612	:	:	:
613	622	Gel-shift	gel-shift	JJ
623	631	analyses	analysis	NNS
632	644	demonstrated	demonstrate	VBD
645	659	dose-dependent	dose-dependent	JJ
660	670	inhibition	inhibition	NN
671	673	of	of	IN
674	685	TNF-induced	tnf-induced	JJ
686	694	NF-kappa	NF-kappa	NNP
695	696	B	B	NNP
697	709	mobilization	mobilization	NN
710	712	by	by	IN
713	720	aspirin	aspirin	NN
721	723	at	at	IN
724	738	concentrations	concentration	NNS
739	746	ranging	range	VBG
747	751	from	from	IN
752	753	1	1	CD
754	756	to	to	TO
757	759	10	10	CD
760	767	mmol/L.	mmol/l.	NN
768	777	Induction	induction	NN
778	780	of	of	IN
781	787	VCAM-1	VCAM-1	NNP
788	791	and	and	CC
792	802	E-selectin	E-selectin	NNP
803	810	surface	surface	NN
811	821	expression	expression	NN
822	824	by	by	IN
825	828	TNF	TNF	NNP
829	832	was	be	VBD
833	849	dose-dependently	dose-dependently	RB
850	857	reduced	reduce	VBN
858	860	by	by	IN
861	868	aspirin	aspirin	NN
869	873	over	over	IN
874	877	the	the	DT
878	882	same	same	JJ
883	888	range	range	NN
888	889	,	,	,
890	895	while	while	IN
896	905	induction	induction	NN
906	908	of	of	IN
909	922	intercellular	intercellular	JJ
923	931	adhesion	adhesion	NN
932	942	molecule-1	molecule-1	NN
943	944	(	(	(
944	950	ICAM-1	icam-1	NN
950	951	)	)	)
952	955	was	be	VBD
956	962	hardly	hardly	RB
963	971	affected	affect	VBN
971	972	.	.	.

973	980	Aspirin	aspirin	NN
981	989	appeared	appear	VBD
990	992	to	to	TO
993	1000	prevent	prevent	VB
1001	1007	VCAM-1	vcam-1	NN
1008	1021	transcription	transcription	NN
1021	1022	,	,	,
1023	1028	since	since	IN
1029	1031	it	it	PRP
1032	1048	dose-dependently	dose-dependently	RB
1049	1058	inhibited	inhibit	VBD
1059	1068	induction	induction	NN
1069	1071	of	of	IN
1072	1078	VCAM-1	VCAM-1	NNP
1079	1083	mRNA	mRNA	NNP
1084	1086	by	by	IN
1087	1090	TNF	TNF	NNP
1090	1091	.	.	.

1092	1094	As	as	IN
1095	1096	a	a	DT
1097	1107	functional	functional	JJ
1108	1119	consequence	consequence	NN
1119	1120	,	,	,
1121	1129	adhesion	adhesion	NN
1130	1132	of	of	IN
1133	1137	U937	u937	NN
1138	1147	monocytes	monocyte	NNS
1148	1150	to	to	TO
1151	1165	TNF-stimulated	tnf-stimulated	JJ
1166	1172	HUVECs	huvec	NNS
1173	1176	was	be	VBD
1177	1185	markedly	markedly	RB
1186	1193	reduced	reduce	VBN
1194	1196	by	by	IN
1197	1204	aspirin	aspirin	NN
1205	1208	due	due	JJ
1209	1211	to	to	TO
1212	1223	suppression	suppression	NN
1224	1226	of	of	IN
1227	1233	VCAM-1	VCAM-1	NNP
1234	1237	and	and	CC
1238	1248	E-selectin	E-selectin	NNP
1249	1261	upregulation	upregulation	NN
1261	1262	.	.	.

1263	1268	These	these	DT
1269	1276	effects	effect	NNS
1277	1279	of	of	IN
1280	1287	aspirin	aspirin	NN
1288	1292	were	be	VBD
1293	1296	not	not	RB
1297	1304	related	related	JJ
1305	1307	to	to	TO
1308	1311	the	the	DT
1312	1322	inhibition	inhibition	NN
1323	1325	of	of	IN
1326	1340	cyclooxygenase	cyclooxygenase	NN
1341	1349	activity	activity	NN
1349	1350	,	,	,
1351	1356	since	since	IN
1357	1369	indomethacin	indomethacin	NN
1370	1373	was	be	VBD
1374	1385	ineffective	ineffective	JJ
1385	1386	.	.	.

1387	1398	CONCLUSIONS	conclusions	NNS
1398	1399	:	:	:
1400	1403	Our	our	PRP$
1404	1408	data	datum	NNS
1409	1416	suggest	suggest	VBP
1417	1421	that	that	IN
1422	1429	aspirin	aspirin	NN
1430	1438	inhibits	inhibit	VBZ
1439	1447	NF-kappa	NF-kappa	NNP
1448	1449	B	B	NNP
1450	1462	mobilization	mobilization	NN
1462	1463	,	,	,
1464	1473	induction	induction	NN
1474	1476	of	of	IN
1477	1483	VCAM-1	VCAM-1	NNP
1484	1487	and	and	CC
1488	1498	E-selectin	E-selectin	NNP
1498	1499	,	,	,
1500	1503	and	and	CC
1504	1514	subsequent	subsequent	JJ
1515	1523	monocyte	monocyte	NN
1524	1532	adhesion	adhesion	NN
1533	1535	in	in	IN
1536	1547	endothelial	endothelial	JJ
1548	1553	cells	cell	NNS
1554	1564	stimulated	stimulate	VBN
1565	1567	by	by	IN
1568	1571	TNF	TNF	NNP
1571	1572	,	,	,
1573	1580	thereby	thereby	RB
1581	1590	providing	provide	VBG
1591	1593	an	an	DT
1594	1604	additional	additional	JJ
1605	1614	mechanism	mechanism	NN
1615	1618	for	for	IN
1619	1630	therapeutic	therapeutic	JJ
1631	1638	effects	effect	NNS
1639	1641	of	of	IN
1642	1649	aspirin	aspirin	NN
1649	1650	.	.	.